Printer Friendly Version
David Abramowitz is Co-Chair of Locke Lord's FDA Regulatory Group and focuses his practice on complex patent litigation brought under the Hatch-Waxman amendments to the Federal Food, Drug and Cosmetic Act and the Biologics Price, Competition, and Innovation Act, where he has significant experience representing and counseling generic pharmaceutical and biotechnology companies in federal intellectual property litigation, and counseling food, drug and cosmetic clients in connection with regulatory issues.
News, Events, Notable Matters, and More
Showing Results for
Please understand that your communications with Locke Lord LLP through this website do not constitute or create an attorney-client relationship with Locke Lord LLP. Any information you send to Locke Lord LLP through this website is on a non-confidential and non-privileged basis. Therefore, do not send or include any information in your email that you consider to be confidential or privileged.